RHEA Generics, a homegrown pioneer in the marketing and distribution of high-quality and affordable health-care products, has entered a new partnership with leading pharmaceutical company Boehringer Ingelheim (Philippines) Inc. The initial offering from this partnership is the launch of an affordable combination medication for the management of reversible bronchospasm associated with obstructive airway diseases that include chronic obstructive pulmonary disease (COPD) and asthma.

Both asthma and COPD fall under respiratory diseases, a group of illnesses consistently ranked among the top causes of death in the Philippines. As of 2018, the morbidity rate of respiratory illnesses in the Philippines was approximately 1.1 thousand per 100,000 people.